Therefore, using CSPG4 as a CAR-T target in solid tumors is attractive because doing so may give CAR-T cells the ability to attack primary and metastatic tumor cells and the tumor-supportive stroma [22]. This evidence concerns the gene CSPG4 and neoplasm.